KYORIN PHARMACEUTICAL CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,714 JPY | +0.82% |
|
+0.82% | -3.71% |
| 2023 | ATyr Pharma to Obtain $10 Million in Milestone Payment After Partner Starts Dosing Patients in Lung Disease Study in Japan | MT |
| 2021 | KYORIN Holdings, Inc.(TSE:4569) dropped from S&P Japan 500 | CI |
Valuation
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 125,915 | 110,478 | 101,826 | 97,646 | 104,097 | 97,663 | - | - |
| Enterprise Value (EV) 1 | 116,590 | 101,516 | 95,956 | 99,529 | 111,058 | 97,663 | 97,663 | 97,663 |
| P/E ratio | 20.5 x | 18 x | 25.9 x | 20.7 x | 19.5 x | 19.2 x | 25.3 x | 27.3 x |
| Yield | 3.41% | 3.89% | 2.93% | 3.05% | 2.87% | 3.06% | 3.06% | 3.06% |
| Capitalization / Revenue | 1.14 x | 1.07 x | 0.96 x | 0.86 x | 0.87 x | 0.78 x | 0.78 x | 0.82 x |
| EV / Revenue | 1.14 x | 1.07 x | 0.96 x | 0.86 x | 0.87 x | 0.78 x | 0.78 x | 0.82 x |
| EV / EBITDA | 11.7 x | 11.8 x | 11.7 x | 10.9 x | 10.1 x | 8.79 x | 10.4 x | 10.8 x |
| EV / FCF | 25,032,756 x | 118,793,961 x | 26,895,291 x | -22,883,951 x | -63,551,437 x | - | - | - |
| FCF Yield | 0% | 0% | 0% | -0% | -0% | - | - | - |
| Price to Book | 1.03 x | 0.89 x | 0.82 x | 0.78 x | 0.8 x | 0.73 x | 0.73 x | 0.73 x |
| Nbr of stocks (in thousands) | 57,286 | 57,302 | 57,302 | 57,304 | 57,449 | 57,449 | - | - |
| Reference price 2 | 2,198 | 1,928 | 1,777 | 1,704 | 1,812 | 1,700 | 1,700 | 1,700 |
| Announcement Date | 5/12/20 | 5/11/21 | 5/11/22 | 5/11/23 | 5/10/24 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 109,983 | 102,904 | 105,534 | 113,270 | 119,532 | 124,600 | 124,600 | 119,300 |
| EBITDA 1 | 10,724 | 9,350 | 8,721 | 8,963 | 10,303 | 11,110 | 9,413 | 9,011 |
| EBIT 1 | 7,503 | 5,786 | 5,007 | 5,123 | 6,013 | 6,500 | 4,800 | 4,400 |
| Operating Margin | 6.82% | 5.62% | 4.74% | 4.52% | 5.03% | 5.22% | 3.85% | 3.69% |
| Earnings before Tax (EBT) 1 | 8,255 | 8,352 | 5,216 | 6,906 | 7,019 | 7,030 | 5,330 | 4,940 |
| Net income 1 | 6,149 | 6,130 | 3,932 | 4,723 | 5,322 | 5,090 | 3,860 | 3,580 |
| Net margin | 5.59% | 5.96% | 3.73% | 4.17% | 4.45% | 4.09% | 3.1% | 3% |
| EPS 2 | 107.4 | 107.0 | 68.62 | 82.44 | 92.74 | 88.60 | 67.20 | 62.30 |
| Free Cash Flow | 5,030 | 930 | 3,786 | -4,267 | -1,638 | - | - | - |
| FCF margin | 4.57% | 0.9% | 3.59% | -3.77% | -1.37% | - | - | - |
| FCF Conversion (EBITDA) | 46.9% | 9.95% | 43.41% | - | - | - | - | - |
| FCF Conversion (Net income) | 81.8% | 15.17% | 96.29% | - | - | - | - | - |
| Dividend per Share 2 | 75.00 | 75.00 | 52.00 | 52.00 | 52.00 | 52.00 | 52.00 | 52.00 |
| Announcement Date | 5/12/20 | 5/11/21 | 5/11/22 | 5/11/23 | 5/10/24 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2021 S1 | 2022 S1 | 2022 Q3 | 2023 Q1 | 2023 S1 | 2023 Q3 | 2024 Q1 | 2024 S1 | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 47,735 | 49,102 | 28,615 | 24,619 | 49,093 | 31,614 | 27,854 | 54,937 | 32,330 |
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 1,502 | -68 | 2,994 | 489 | 777 | 3,925 | 710 | 1,144 | 3,321 |
| Operating Margin | 3.15% | -0.14% | 10.46% | 1.99% | 1.58% | 12.42% | 2.55% | 2.08% | 10.27% |
| Earnings before Tax (EBT) 1 | 2,874 | 269 | 3,229 | 1,658 | 1,812 | 4,149 | 913 | 2,349 | 2,801 |
| Net income 1 | 2,118 | 121 | 2,362 | 1,183 | 1,242 | 3,135 | 676 | 1,757 | 2,157 |
| Net margin | 4.44% | 0.25% | 8.25% | 4.81% | 2.53% | 9.92% | 2.43% | 3.2% | 6.67% |
| EPS 2 | 36.98 | 2.120 | 41.22 | 20.65 | 21.69 | 54.71 | 11.81 | 30.66 | 37.57 |
| Dividend per Share | 30.00 | 20.00 | - | - | 20.00 | - | - | 20.00 | - |
| Announcement Date | 11/5/20 | 11/8/21 | 2/4/22 | 8/2/22 | 11/9/22 | 2/6/23 | 8/2/23 | 11/8/23 | 2/6/24 |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | 1,883 | 6,961 | - | - | - |
| Net Cash position | 9,325 | 8,962 | 5,870 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | 0.2101 x | 0.6756 x | - | - | - |
| Free Cash Flow | 5,030 | 930 | 3,786 | -4,267 | -1,638 | - | - | - |
| ROE (net income / shareholders' equity) | 5% | 5% | 3.2% | 3.8% | 4.2% | 3.9% | 2.9% | 2.7% |
| ROA (Net income/ Total Assets) | 4.75% | 3.81% | 3.29% | 3.35% | 3.73% | 2.8% | 2.1% | 2% |
| Assets 1 | 129,446 | 160,826 | 119,693 | 141,021 | 142,572 | 181,786 | 183,810 | 179,000 |
| Book Value Per Share 2 | 2,142 | 2,176 | 2,173 | 2,189 | 2,277 | 2,313 | 2,328 | 2,339 |
| Cash Flow per Share 2 | 164.0 | 169.0 | 133.0 | 149.0 | 167.0 | 167.0 | 146.0 | 141.0 |
| Capex 1 | 2,709 | 4,259 | 2,560 | 5,252 | 5,778 | 6,000 | 2,000 | 2,000 |
| Capex / Sales | 2.46% | 4.14% | 2.43% | 4.64% | 4.83% | 4.82% | 1.61% | 1.68% |
| Announcement Date | 5/12/20 | 5/11/21 | 5/11/22 | 5/11/23 | 5/10/24 | - | - | - |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
1
Last Close Price
1,700
JPY
Average target price
1,300
JPY
Spread / Average Target
-23.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.71% | 604M | |
| +61.22% | 846B | |
| +39.61% | 628B | |
| -4.66% | 360B | |
| +16.77% | 322B | |
| +8.50% | 297B | |
| +14.64% | 240B | |
| +18.06% | 223B | |
| +3.39% | 224B | |
| +11.68% | 173B |
- Stock Market
- Equities
- 4569 Stock
- Financials KYORIN Pharmaceutical Co., Ltd.
